

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ENSS M -L ET AL: "Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180" INFLAMMATION RESEARCH, vol. 49, no. 4, April 2000 (2000-04), pages 162-169, XP008043079 ISSN: 1023-3830 the whole document ----- -/--	1-29

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *G* document member of the same patent family

Date of the actual completion of the international search

26 May 2005

Date of mailing of the international search report

10/06/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SKEBERDIS VYTENIS A ET AL: "Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis"</p> <p>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 6, 13 March 2001 (2001-03-13), pages 3561-3566, XP008043078</p> <p>ISSN: 0027-8424</p> <p>abstract</p> <p>page 3562, right-hand column, line 1 -</p> <p>page 3563, left-hand column, last line</p> <p>-----</p>	1-29
X	<p>JAYAWICKREME S P ET AL: "Regulation of 15-lipoxygenase expression and mucus secretion by IL-4 in human bronchial epithelial cells"</p> <p>AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY 1999 UNITED STATES, vol. 276, no. 4 20-4, 1999, pages L596-L603, XP008043082</p> <p>ISSN: 1040-0605</p> <p>page L600, right-hand column, last paragraph - page L601, right-hand column, line 2</p> <p>-----</p>	1-29
X	<p>ENSS M -L ET AL: "Proinflammatory cytokines differentially affect mucin expression in LS180 cells"</p> <p>GASTROENTEROLOGY, vol. 114, no. 4 PART 2, 15 April 1998 (1998-04-15), page A973, XP008043029</p> <p>& DIGESTIVE DISEASES WEEK AND THE 99TH ANNUAL MEETING OF THE AMERICAN GASTROENTEROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; MAY 16-22, 1998</p> <p>ISSN: 0016-5085</p> <p>abstract no. G3987</p> <p>the whole document</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1-29

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ABDULLA P ET AL: "GTP and Ca-2+ - dependent mucin secretion in permeabilized LS180 human colonic cancer cells: Modulation by anion substitution" FASEB JOURNAL, vol. 11, no. 3, 1997, page A516, XP008043069</p> <p>& ANNUAL MEETING OF THE PROFESSIONAL RESEARCH SCIENTISTS ON EXPERIMENTAL BIOLOGY 97; NEW ORLEANS, LOUISIANA, USA; APRIL 6-9, 1997 ISSN: 0892-6638 abstract no. 2989 the whole document</p>	1-29
X	<p>DEBINSKI W ET AL: "A NOVEL CHIMERIC PROTEIN COMPOSED OF INTERLEUKIN-13 AND PSEUDOMONAS EXOTOXIN IS HIGHLY CYTOTOXIC TO HUMAN CARCINOMA CELLS EXPRESSING RECEPTORS FOR INTERLEUKIN-13 AND INTERLEUKIN-4" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 28, 14 July 1995 (1995-07-14), pages 16775-16780, XP002011861 ISSN: 0021-9258 the whole document</p>	1-13,28, 29
X	<p>WO 98/07864 A (MICROBIOLOGICAL RESEARCH AUTHORITY CAMR (CENTRE FO; THE SPEYWOOD LABOR) 26 February 1998 (1998-02-26) examples</p>	1-13,28, 29
X	<p>WO 94/21300 A (THE SPEYWOOD LABORATORY LTD; PUBLIC HEALTH LABORATORY SERVICE BOARD; N) 29 September 1994 (1994-09-29) claim 14</p>	1-13,28, 29
X	<p>EP 0 467 536 A (MERCK & CO. INC; MERCK & CO., INC) 22 January 1992 (1992-01-22) examples</p>	1-13,28, 29
X	<p>LI DAILIN ET AL: "Hyperosmolarity reduces GLUT4 endocytosis and increases its exocytosis from a VAMP2-independent pool in L6 muscle cells" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 25, 22 June 2001 (2001-06-22), pages 22883-22891, XP002329525 ISSN: 0021-9258 page 22883, right-hand column figures 1,2,10</p>	14-29
	----- -/--	

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>OLSON ANN LOUISE ET AL: "Insulin-mediated GLUT4 translocation is dependent on the microtubule network"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 14, 6 April 2001 (2001-04-06), pages 10706-10714, XP002329526</p> <p>ISSN: 0021-9258</p> <p>page 10706, right-hand column, paragraph 2 - paragraph 3</p> <p>page 10712, right-hand column, paragraph DISCUSSION</p> <p>-----</p>	14-29
X	<p>YANG CHUN ZHI ET AL: "ADP-ribosylation factor 6 (ARF6) defines two insulin-regulated secretory pathways in adipocytes"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 36, 3 September 1999 (1999-09-03), pages 25297-25300, XP002329527</p> <p>ISSN: 0021-9258</p> <p>abstract</p> <p>page 25297, right-hand column, paragraph 2</p> <p>-----</p>	14-29
X	<p>CAIN C C ET AL: "MEMBERS OF THE VAMP FAMILY OF SYNAPTIC VESICLE PROTEINS ARE COMPONENTS OF GLUCOSE TRANSPORTER-CONTAINING VESICLES FROM RAT ADIPOCYTES"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 17, 1992, pages 11681-11684, XP002329528</p> <p>ISSN: 0021-9258</p> <p>abstract</p> <p>page 11684, left-hand column, paragraph CONCLUSIONS - right-hand column</p> <p>-----</p>	14-29
X	<p>DAVIS R J ET AL: "INSULIN-LIKE GROWTH FACTOR I AND EPIDERMAL GROWTH FACTOR REGULATE THE EXPRESSION OF TRANSFERRIN RECEPTORS AT THE CELL SURFACE BY DISTINCT MECHANISMS"</p> <p>JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 262, no. 27, 1987, pages 13126-13134, XP002329529</p> <p>ISSN: 0021-9258</p> <p>abstract</p> <p>page 13128, left-hand column, line 6 - right-hand column, line 2</p> <p>figures 1-4</p> <p>-----</p>	14-29

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-13, 28 and 29 in part
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-29
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☒ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 28-29 in part, and 1-13

Method of designing a non-cytotoxic toxin as defined by these claims

2. claims: 28-29 in part, and 14-27

Method of identifying an agonist as defined in these claims.

3. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is IL-13

4. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is insulin

5. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is mast cell degranulating peptide.

6. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is IL-4

7. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is TNF alpha

8. claims: 30-43 and 48-57 in part

Pharmaceutical composition and its use (in a method of treatment) as defined in these claims, in which the TM of the agent is EGF.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. claims: 44-45

DNA construct as defined in claim 44, and its use in the preparation of a chimeric agent as defined in claim 45

10. claims: 46-47

Process of preparing a conjugate as defined in these claims, i.e., by conjugation rather than by expression of a single DNA construct.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.2

Claims Nos.: 1-13, 28 and 29 in part

Claims 1-13, 28 and 29 encompass a genus of compounds defined only by their function wherein the relationship between the structural features of the members of the genus and said function have not been defined. In the absence of such a relationship either disclosed in the as-filed application or which would have been recognized based upon information readily available to one skilled in the art, the skilled artisan would not know how to make and use compounds that lack structural definition. The fact that one could have assayed a compound of interest using the claimed assays does not overcome this defect since one would have no knowledge beforehand as to whether or not any given compound (other than those that might be particularly disclosed in an application) would fall within the scope of what is claimed. It would require undue experimentation (be an undue burden) to randomly screen undefined compounds for the claimed activity. Therefore, the search for claims 1-13, 28 and 29 has been limited to the examples (Art. 5 and Art. 6 PCT), insofar as relating to the first invention.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

PCT/GB2004/003904

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9807864	A	26-02-1998	AT 294238 T	15-05-2005
			AU 723397 B2	24-08-2000
			AU 4389597 A	06-03-1998
			CA 2264191 A1	26-02-1998
			EP 0939818 A1	08-09-1999
			WO 9807864 A1	26-02-1998
			JP 2001502890 T	06-03-2001
			US 2003166238 A1	04-09-2003
			US 2002044950 A1	18-04-2002
			ZA 9707541 A	16-04-1998
WO 9421300	A	29-09-1994	AT 228856 T	15-12-2002
			AU 671203 B2	15-08-1996
			AU 6217594 A	11-10-1994
			BR 9406232 A	09-01-1996
			CA 2158647 A1	29-09-1994
			CN 1124929 A	19-06-1996
			CZ 9502426 A3	17-04-1996
			DE 69431832 D1	16-01-2003
			DE 69431832 T2	10-04-2003
			DK 689459 T3	24-03-2003
			EP 0689459 A1	03-01-1996
			ES 2183836 T3	01-04-2003
			FI 954390 A	17-11-1995
			WO 9421300 A2	29-09-1994
			HU 76556 A2	29-09-1997
			IN 178499 A1	03-05-1997
			JP 9500867 T	28-01-1997
			NO 953643 A	16-11-1995
			NZ 262484 A	27-08-1996
			PL 310698 A1	27-12-1995
			PT 689459 T	30-04-2003
			SG 73411 A1	20-06-2000
			SK 115595 A3	05-02-1997
EP 0467536	A	22-01-1992	AT 173274 T	15-11-1998
			AU 645094 B2	06-01-1994
			AU 7918991 A	02-01-1992
			CA 2044858 A1	22-12-1991
			DE 69130466 D1	17-12-1998
			DE 69130466 T2	02-06-1999
			DK 467536 T3	26-07-1999
			EP 0467536 A2	22-01-1992
			EP 0868920 A2	07-10-1998
			ES 2122968 T3	01-01-1999
			FI 913058 A	22-12-1991
			IE 912130 A1	01-01-1992
			JP 1988090 C	08-11-1995
			JP 5092999 A	16-04-1993
			JP 7021000 B	08-03-1995
			NO 912418 A	23-12-1991
			PT 98048 A , B	30-04-1992
			US 5690928 A	25-11-1997
			ZA 9104757 A	25-03-1992